SRR2932834
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.470
- MYC_TARGETS_V2+0.290
- E2F_TARGETS+0.270
- SPERMATOGENESIS+0.230
- INTERFERON_GAMMA_RESPONSE+0.220
- DNA_REPAIR+0.190
- G2M_CHECKPOINT+0.190
- P53_PATHWAY+0.180
- FATTY_ACID_METABOLISM+0.080
- ESTROGEN_RESPONSE_EARLY+0.070
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.560
- ANGIOGENESIS-0.440
- TGF_BETA_SIGNALING-0.440
- KRAS_SIGNALING_UP-0.410
- PROTEIN_SECRETION-0.400
- UV_RESPONSE_DN-0.360
- ANDROGEN_RESPONSE-0.310
- PANCREAS_BETA_CELLS-0.310
- INFLAMMATORY_RESPONSE-0.300
- TNFA_SIGNALING_VIA_NFKB-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R93 | — | — | 0.837 |
| 2 | R68 | — | — | 0.816 |
| 3 | SRR12475146 | — | — | 0.812 |
| 4 | TCGA-UF-A719-01A-12R-A34R-07 | — | — | 0.812 |
| 5 | 2d8478f6-41ac-47f5-ac3c-337af7245f5b | — | — | 0.802 |
| 6 | SRR33532821 | — | D | 0.800 |
| 7 | TCGA-NC-A5HQ-01A-11R-A26W-07 | — | cohortSQ1 | 0.793 |
| 8 | MNG1109 | — | — | 0.790 |
| 9 | SRR35579830 | — | B | 0.786 |
| 10 | MBCProject_4423_T1_RNA | — | B | 0.786 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.470 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.290 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.270 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.230 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.220 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.190 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.190 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.180 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.080 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.070 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.070 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.060 | Temsirolimus | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.040 | Remibrutinib | — uncovered |
| PEROXISOME | 0.040 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.020 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.020 | Idelalisib | — uncovered |